greeksoup/ stock research

Kewaunee Scientific (KEQU) Q2 FY2025 earnings: revenue $48 million, down 5.3% on the year

Kewaunee Scientific Corp. (KEQU) reported revenue of $48 million for Q2 FY2025, the quarter ended 31 October 2024, down 5.3% on the same quarter a year earlier. Net income was $3 million, up 10.1% on the year, and diluted earnings per share $1.01. The figures are the company's own, from the 10-Q it filed with the SEC on 13 December 2024.

Revenue$48 milliondown 5.3%
Net income$3 millionup 10.1%
Diluted EPS$1.01
QuarterQ2 FY2025ended 31 October 2024

The quarter, against the one before and a year earlier

LineQ2 FY2025Q1 FY2025Q2 FY2024Change on the year
Revenue47.848.450.4-5.3%
Cost of revenue33.835.937.0-8.5%
Gross profit14.012.513.5+3.6%
Gross margin29.2%25.8%26.7%
Operating income4.42.65.1-13.2%
Operating margin9.3%5.3%10.1%
Interest expense0.40.50.4+18.8%
Pre-tax income3.92.44.8-18.9%
Income tax0.90.22.0-54.5%
Effective tax rate23.3%7.9%41.6%
Net income3.02.22.7+10.1%
Net margin6.3%4.5%5.4%
Diluted EPS$1.01$0.74$0.93+8.6%
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ2 FY2025Q1 FY2025Q2 FY2024Change on the year
Operating cash flow8.4-0.80.7+1029.3%
Capital expenditure0.70.31.3-46.0%
Free cash flow7.8-1.1-0.5n/a
Free cash flow margin16.2%-2.2%-1.0%
Cash from investing-0.7-0.3-1.3n/a
Cash from financing-3.20.30.8n/a
Depreciation and amortisation0.80.8n/an/a
Share-based compensation0.40.30.2+54.8%
Diluted shares, weighted3m3m3m+1.5%
Shares outstanding at period end3m3m3m-1.0%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ2 FY2025Q1 FY2025Q2 FY2024Change on the year
Shareholders' equity59.356.042.1+40.9%
Non-controlling interest1.31.51.3+1.8%
Operating lease liabilities5.05.16.2-18.7%
Finance lease liabilities0.20.20.3-39.8%
Other liabilities68.669.271.8-4.5%
Total liabilities and equity134132122+10.5%
Fixed assets17.017.117.8-4.7%
Cash and equivalents26.024.213.7+89.2%
Receivables41.943.542.6-1.7%
Inventory18.719.321.7-13.9%
Other assets31.027.925.9+19.7%
Total assets134132122+10.5%

Questions

What was Kewaunee Scientific's revenue in Q2 FY2025?

Kewaunee Scientific (KEQU) reported revenue of $48 million for Q2 FY2025, the quarter ended 31 October 2024, down 5.3% on the same quarter a year earlier.

How much did Kewaunee Scientific earn in Q2 FY2025?

Net income for Q2 FY2025 was $3 million, up 10.1% on the year, and diluted earnings per share $1.01.

When did Kewaunee Scientific report Q2 FY2025 results?

Kewaunee Scientific filed its 10-Q for the quarter ended 31 October 2024 with the SEC on 13 December 2024.

Quarterly results, the last 20 quarters

Q2 FY2022Q3 FY2022Q4 FY2022Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026 *Q1 FY2027
Revenue39.040.649.750.154.660.854.049.850.446.856.748.447.867.277.171.170.169.471.466.3
Cost of revenue35.435.040.443.945.950.543.637.937.034.742.135.933.848.853.150.250.450.950.246.7
Gross profit3.65.69.36.28.710.310.411.913.512.014.612.514.018.424.020.919.718.521.219.6
Gross margin9%14%19%12%16%17%19%24%27%26%26%26%29%27%31%29%28%27%30%30%
Operating income-2.9-0.92.2-0.40.82.32.73.85.13.85.62.64.42.28.54.84.12.65.23.2
Operating margin-7%-2%5%-1%1%4%5%8%10%8%10%5%9%3%11%7%6%4%7%5%
Interest expense0.10.20.20.40.40.40.50.40.40.40.60.50.41.11.21.11.11.10.60.6
Pre-tax income-2.9-0.92.3-0.30.52.12.33.44.83.51.32.43.91.37.13.93.51.64.82.6
Tax raten/an/a114%n/a125%47%53%26%42%28%-730%8%23%-8%31%19%26%33%22%28%
Net income-3.1-1.3-0.4-0.7-0.20.71.02.52.72.511.02.23.01.44.83.12.40.73.41.7
Net margin-8%-3%-1%-1%-0%1%2%5%5%5%19%5%6%2%6%4%3%1%5%3%
Diluted EPS-$1.11-$0.47-$0.13-$0.27-$0.09$0.25$0.34$0.86$0.93$0.85$3.71$0.74$1.01$0.45$1.63$1.04$0.82$0.23$1.13$0.58
Operating cash flow-4.35.0-6.83.7-4.3-3.0-0.28.20.79.51.1-0.88.4-2.39.45.8-4.311.65.52.0
Capital expenditure0.40.30.70.40.50.62.61.71.30.51.00.30.70.70.50.81.60.70.90.8
Free cash flow-4.74.7-7.53.3-4.8-3.6-2.86.5-0.59.00.2-1.17.8-3.08.95.0-5.811.04.51.2
Buybacksn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a0.0n/an/an/a0.5
Shares outstanding3m3m3m3m3m3m3m3m3m3m3m3m3m3m3m3m3m3m3m3m
Filing10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 31 October 2024, filed 13 December 2024: the filing.